Genolution

Genolution FCF/Net Income

The Free Cash Flow to Net Income Ratio of Genolution (225220.KQ) as of Oct 22, 2026 is 64.03 %. In the previous year, Free Cash Flow to Net Income Ratio was 199.53 % — a change of -67.91% (lower).

FCF/Net Income

64.03 %

YoY

-67.91%

Last updated:

Free Cash Flow to Net Income Ratio of Genolution is 2025 64.03 % . Free Cash Flow to Net Income Ratio of Genolution was 2024 199.53 % . It decreases by -67.91% lower compared to the previous year.

The Genolution FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
-214.86 KRW
Jan 1, 2019
1,123.82 KRW
Jan 1, 2020
116.36 KRW
Jan 1, 2021
59.90 KRW
Jan 1, 2022
-61.59 KRW
Jan 1, 2023
144.47 KRW
Jan 1, 2024
199.53 KRW
Jan 1, 2025
64.03 KRW
The Genolution FCF/Net Income history
YEARFCF/Net IncomeYoY
64.03 %-67.91%
199.53 %+38.11%
144.47 %-334.56%
-61.59 %-202.83%
59.90 %-48.52%
116.36 %-89.65%
1,123.82 %-623.04%
-214.86 %+758.07%
-25.04 %-94.25%
-435.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Free Cash Flow to Net Income Ratio of Genolution is 64.03 % in 2025.

Free Cash Flow to Net Income Ratio of Genolution changed from 199.53 % to 64.03 %, representing a -67.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genolution

All Key Metrics — Genolution